ATAI Life Sciences NV - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ATAI Nasdaq 8731 https://atai.life/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ATAI Life Sciences NV

atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights - Mar 24th, 2023 10:59 am
atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates - Mar 6th, 2023 12:00 pm
atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference - Mar 1st, 2023 9:01 pm
This Analyst Still Has Confidence In Atai Life Sciences' Pipeline Despite Recent Setbacks - Jan 19th, 2023 6:24 pm
Trippy Trading: Top Psychedelic Stocks For 2023 - Jan 17th, 2023 10:00 am
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Jan 9th, 2023 12:00 pm
atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917 - Jan 9th, 2023 11:59 am
Atai Life Sciences' Depression Candidate Faces Trial Setback, Shares Nosedive - Jan 6th, 2023 3:38 pm
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression - Jan 6th, 2023 12:00 pm
atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101 - Dec 23rd, 2022 11:59 am
atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia - Dec 19th, 2022 11:59 am
The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital - Dec 16th, 2022 3:00 pm
atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer - Nov 29th, 2022 11:59 am
atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment - Nov 17th, 2022 12:00 pm
atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update - Nov 10th, 2022 11:59 am
Women in Psychedelics Announces atai as Platinum Sponsors - Nov 4th, 2022 1:35 pm
atai Life Sciences to Participate in November Investor Events & Healthcare Conferences - Nov 1st, 2022 4:00 pm
atai Life Sciences to Announce Third Quarter 2022 Financial Results and Business Update - Nov 1st, 2022 11:00 am
atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression - Oct 25th, 2022 11:03 am
atai Life Sciences Announces R&D Day Agenda - Oct 20th, 2022 10:59 am